Sonitrack Systems, Inc.

1114 Boranda Ave
Mountain View, CA 94040

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $529K
First Award Date 09/24/12
Most Recent Award Date 01/01/14

Key Personnel

Last Name Name Awards Contact
Hristov Dimitre Hristov Hristov 3
Schlosser Jeffrey Steven Schlosser 3
Schlosser Jeff Schlosser 2 Message

4 Awards Won

Phase 1 SBIR

Agency: National Science Foundation
Topic: BC-2013
Budget: 01/01/14 - 12/31/14

This Small Business Innovation Research (SBIR) Phase I project seeks to develop a novel ultrasound device for improving the precision of radiation therapy delivery for cancer treatment. In external beam radiation therapy (EBRT), highly potent radiation doses with minimal treatment margins must be precisely delivered to maximize chances of local ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-12-100
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): External Beam Radiation Therapy (EBRT) is used in the disease management of more than half of all cancer patients worldwide. In order to advance the field of EBRT and improve treatment outcomes, highly conformal, potent ablative doses must be delivered to maximize local tumor control and minimize toxicity to ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-10-080
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): External Beam Radiation Therapy (EBRT) is used in the disease management of more than half of all cancer patients worldwide. In order to advance the field of EBRT and improve treatment outcomes, highly conformal, potent ablative doses must be delivered to maximize local tumor control and minimize toxicity to ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-10-080
Budget: 09/24/12 - 08/31/13

DESCRIPTION (provided by applicant): External Beam Radiation Therapy (EBRT) is used in the disease management of more than half of all cancer patients worldwide. In order to advance the field of EBRT and improve treatment outcomes, highly conformal, potent ablative doses must be delivered to maximize local tumor control and minimize toxicity to ...